|Application ||WB, IHC-P, E|
|Calculated MW||10963 Da|
|Antigen Region||2-32 aa|
|Other Names||Osteocalcin, Bone Gla protein, BGP, Gamma-carboxyglutamic acid-containing protein, BGLAP|
|Target/Specificity||This Osteocalcin antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 2-32 amino acids from the N-terminal region of human Osteocalcin.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||Osteocalcin Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Constitutes 1-2% of the total bone protein. It binds strongly to apatite and calcium.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Prior to the formation of calcified bone, noncollagenous proteins form in the extracellular bone matrix. Gamma-carboxyglutamic acid residues are formed by vitamin K, vitamin-D regulated calcium binding proteins containing residues of Gla. These residues are essential for the binding of calcium and constitue 1-2% of total bone protein. Osteocalcin itself binds strongly to apatite and calcium. Production of osteocalcin is expressed late in normal bone development and is characteristic of mature osteoblasts. Regular osteocalcin production has been shown to be linked to the p53 tumor suppressor gene. The p53 gene undergoes rearrangement in a high percentage of osteosarcomas, resulting in loss of its expression. The loss of p53 regulation inhibits further osteocalcin production. The absence of end-point differentiation in bone due to p53 rearrangements and lack of osteocalcin production may contribute to the maintenance of the tumorigenic phenotype in osteosarcomas.
Yamada, Y., et al., J. Clin. Endocrinol. Metab. 88(7):3372-3378 (2003). Gronthos, S., et al., J. Bone Miner. Res. 18(4):716-722 (2003). Yousfi, M., et al., Biochem. Biophys. Res. Commun. 297(3):641-644 (2002). Willis, D.M., et al., J. Biol. Chem. 277(40):37280-37291 (2002). Viereck, V., et al., J. Cell. Biochem. 86(2):348-356 (2002).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.